Tuesday, April 04, 2017 11:04:55 AM
a.
General
Orgenesis Inc. (the “Company”) was incorporated in the state of Nevada on June 5, 2008, under the name Business Outsourcing Services, Inc. Effective August 31, 2011, the Company completed a merger with its subsidiary, Orgenesis Inc., a Nevada corporation which was incorporated solely to effect a change in its name. As a result, the Company changed its name from “Business Outsourcing Services, Inc.” to “Orgenesis Inc.” The consolidated financial statements include the accounts of Orgenesis Inc., its wholly-owned subsidiaries MaSTherCell S.A (the “MaSTherCell”), its Belgian based subsidiary and a contract development manufacturing organization, or CDMO (see also note 3), specialized in cell therapy development for advanced medicinal products; Orgenesis SPRL (the “Belgian Subsidiary”), a Belgian based subsidiary which is engaged in development and manufacturing activities together with clinical development studies in Europe, and later on to be the Company’s center for activities in Europe; Orgenesis Maryland Inc. (the “U.S. Subsidiary”) a Maryland corporation, and Orgenesis Ltd. an Israeli corporation.
The Company is a regenerative therapy company with expertise and experience in cell therapy development and manufacturing.
The Company’s cell therapy technology derives from published work of Prof. Sarah Ferber, our Chief Science Officer and a researcher at Tel Hashomer Medical Research (“THM”), a leading medical hospital and research center in Israel, who established a proof of concept that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and transdifferentiating (converting) them into “pancreatic beta cell-like” insulin-producing cells. Its development activities with respect to cell-derived and related therapies, which are conducted through Orgenesis Ltd. (the “Israeli Subsidiary”), have, to date, been limited to laboratory and preclinical testing.
Recent ORGS News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/06/2024 07:30:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 07:28:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/06/2024 07:26:43 PM
- Orgenesis Provides Year End Business Update • GlobeNewswire Inc. • 04/15/2024 09:07:16 PM
- Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility • GlobeNewswire Inc. • 04/10/2024 04:00:00 PM
- Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference • GlobeNewswire Inc. • 03/18/2024 12:30:00 PM
- Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
- Orgenesis Inc. Announces $2.3 Million Private Placement • GlobeNewswire Inc. • 03/04/2024 01:30:00 PM
- Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing • GlobeNewswire Inc. • 02/29/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 02:20:12 PM
- Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic • GlobeNewswire Inc. • 01/31/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 11:02:39 AM
- Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM • GlobeNewswire Inc. • 11/14/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:15:50 PM
- Orgenesis Provides Business Update for the Third Quarter of 2023 • GlobeNewswire Inc. • 11/13/2023 09:15:50 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/09/2023 12:41:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 02:24:05 PM
- Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering • GlobeNewswire Inc. • 11/08/2023 02:00:10 PM
- Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Orgenesis Announces Withdrawal of Proposed Public Offering • GlobeNewswire Inc. • 10/31/2023 01:30:00 AM
- Orgenesis Announces Proposed Underwritten Public Offering • GlobeNewswire Inc. • 10/30/2023 08:07:26 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM